Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket
--------------------------------------------------------------------
Source: CNBC
Published: 2026-04-30 20:15 UTC+10:00
Section: General
Factuality Score: 100
Opinion Category: Neutral
Topics: Health, Financial Markets, Drugs
--------------------------------------------------------------------
Snippet:
Eli Lilly on Thursday reported first-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook by $2 billion, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro spiked again.
--------------------------------------------------------------------